Skip to main content
. 2022 Aug 28;149(7):3951–3963. doi: 10.1007/s00432-022-04301-w

Table 2.

Clinico-pathological data of 61 patients with triple negative breast cancer based on BCL11A gene expression

BCL11A BCL11A_XL BCL11A_L BCL11A_S
Down Up p-value Down Up p-value Down Up p-value Down Up p-value
Age at diagnosis (years)
  ≤ 50 15 (31.9) 7 (50.0) 0.22 12 (32.4) 9 (40.9) 0.51 10 (28.6) 8 (50.0) 0.14 14 (33.3) 4 (66.7) 0.18
  > 50 32 (68.1) 7 (50.0) 25 (67.6) 13 (59.1) 25 (71.4) 8 (50.0) 28 (66.7) 2 (33.3)
Menstrual Status
 Yes, physiological 11 (50.0) 2 (33.3) 0.83 9 (47.4) 3 (37.5) 0.85 8 (44.4) 2 (40.0) 0.98 10 (47.6) 0 (0.0) 0.31
 Yes, post-surgical 3 (13.6) 1 (16.7) 3 (15.8) 1 (12.5) 3 (16.7) 1 (20.0) 4 (19.1) 0 (0.0)
 No 8 (36.4) 3 (50.0) 7 (36.8) 4 (50.0) 7 (38.9) 2 (40.0) 7 (33.3) 2 (100.0)
Site
 Right 21 (47.7) 10 (71.4) 0.41 18 (52.9) 12 (54.6) 1.00 16 (48.5) 9 (56.3) 0.72 17 (42.5) 5 (83.3) 0.21
 Left 22 (50.0) 4 (28.6) 15 (44.1) 10 (45.5) 16 (48.5) 9 (56.3) 22 (55.0) 1 (16.7)
 Bilateral 1 (2.3) 0 (0.0) 1 (2.9) 0 (0.0) 1 (3.0) 0 (0.0) 1 (2.5) 0 (0.0)
Histological subtype
 Invasive ductal carcinoma (NST) 32 (68.1) 8 (57.1) 0.80 27 (73.0) 13 (59.1) 0.36 27 (77.1) 7 (43.8) 0.04 29 (69.1) 2 (33.3) 0.17
 Medullary carcinoma 6 (12.8) 3 (21.4) 3 (8.1) 5 (22.7) 3 (8.6) 4 (25.0) 5 (11.9) 2 (33.3)
 Metaplastic carcinoma 3 (6.4) 1 (7.1) 2 (5.4) 2 (9.1) 1 (2.9) 3 (18.8) 3 (7.1) 1 (16.7)
 Other 6 (12.8) 2 (14.3) 5 (13.5) 2 (9.1) 4 (11.4) 2 (12.5) 5 (11.9) 1 (16.7)
Tumor size (cm)
  ≤ 20 mm 26 (55.3) 8 (57.1) 0.90 19 (51.4) 13 (59.1) 0.56 18 (51.4) 10 (62.5) 0.46 24 (57.19 3 (50.0) 1.00
  > 20 mm 21 (44.7) 6 (42.9) 18 (48.7) 9 (40.9) 17 (48.6) 6 (37.5) 18 (42.9) 3 (50.0)
Histologic grade
 G1 1 (2.1) 2 (14.3) 0.20 1 (2.7) 2 (9.1) 0.38 1 (2.9) 2 (12.5) 0.28 2 (4.8) 1 (16.7) 0.25
 G2 7 (14.9) 1 (7.1) 4 (10.8) 4 (18.2) 5 (14.3) 3 (18.8) 8 (19.1) 0 (0.0)
 G3 39 (83.0) 11 (78.6) 32 (86.5) 16 (72.7) 29 (82.9) 11 (68.8) 32 (76.2) 5 (83.3)
Pathologic tumor classification
 pT1 17 (38.6) 7 (58.3) 0.65 11 (32.4) 11 (55.0) 0.20 11 (35.5) 8 (53.3) 0.39 16 (42.1) 2 (40.0) 1.00
 pT2 21 (47.7) 5 (41.7) 17 (50.0) 9 (45.0) 14 (45.2) 7 (46.7) 17 (44.7) 3 (60.0)
 pT3 3 (6.8) 0 (0.0) 3 (8.8) 0 (0.0) 3 (9.7) 0 (0.0) 3 (7.9) 0 (0.0)
 pT4 3 (6.8) 0 (0.0) 3 (8.8) 0 (0.0) 3 (9.7) 0 (0.0) 2 (5.3) 0 (0.0)
Regional lymph nodes involvement
 pN0 23 (52.3) 8 (57.1) 0.68 16 (45.7) 13 (61.9) 0.33 14 (42.4) 8 (53.3) 0.44 18 (46.2) 3 (50.0) 0.84
 pN1 11 (25.0) 5 (35.7) 10 (28.6) 6 (28.6) 10 (30.3) 6 (40.0) 12 (30.8) 3 (50.0)
 pN2 5 (11.4) 1 (7.1) 4 (11.4) 2 (9.5) 4 (12.1) 1 (6.7) 5 (12.8) 0 (0.0)
 pN3 5 (11.4) 0 (0.0) 5 (14.3) 0 (0.0) 5 (15.2) 0 (0.0) 4 (10.3) 0 (0.0)
Tumor stage
 I 10 (23.8) 3 (25.0) 0.46 5 (15.2) 6 (31.6) 0.18 6 (20.0) 3 (21.4) 0.18 8 (22.2) 0 (0.0) 0.21
 II 21 (50.0) 8 (66.7) 18 (54.6) 11 (57.9) 14 (46.7) 10 (71.49 18 (50.0) 5 (100.0)
 III 11 (26.2) 1 (8.3) 10 (30.3) 2 (10.5) 10 (33.3) 1 (7.1) 10 (27.8) 0 (0.0)
Necrosis
 Present 16 (37.2) 4 (28.6) 0.75 15 (44.1) 5 (22.7) 0.10 12 (36.4) 4 (25.0) 0.53 13 (32.5) 2 (33.3) 1.00
 Absent 27 (62.8) 10 (71.4) 19 (55.9) 17 (77.3) 21 (63.6) 12 (75.0) 27 (67.5) 4 (66.7)
Tumor infiltrating lymphocytes
 Present 20 (52.6) 7 (53.9) 1.00 15 (51.7) 11 (52.4) 1.00 13 (46.4) 8 (53.3) 0.76 16 (44.4) 4 (80.0) 0.18
 Absent 18 (47.4) 6 (46.2) 14 (48.3) 10 (47.6) 15 (53.6) 7 (46.7) 20 (55.6) 1 (20.0)
Lymph vascular invasion
 Present 8 (21.1) 5 (38.5) 0.21 7 (24.1) 6 (28.6) 0.72 7 (25.0) 3 (20.0) 1.00 8 (22.2) 2 (40.0) 0.58
 Absent 30 (78.9) 8 (61.5) 22 (75.9) 15 (71.4) 21 (75.0) 12 (80.0) 28 (77.8) 3 (60.0)
Ki 67
  ≤ 20% 11 (23.9) 1 (7.1) 0.26 8 (22.2) 3 (13.6) 0.51 9 (26.5) 1 (6.3) 0.14 9 (22.0) 0 (0.0) 0.58
  > 20% 35 (76.1) 13 (92.9) 28 (77.8) 19 (86.4) 25 (73.5) 15 (93.8) 32 (78.1) 6 (100.0)
Androgen receptor
  < 10% 26 (61.9) 12 (92.3) 0.05 20 (60.6) 18 (85.7) 0.07 18 (56.3) 13 (86.7) 0.05 23 (59.0) 5 (100.0) 0.14
  ≥ 10% 16 (38.1) 1 (7.7) 13 (39.4) 3 (14.3) 14 (43.8) 2 (13.3) 16 (41.0) 0 (0.0)
Protein expression BCL11A
 Low: 0–3 41 (87.2) 4 (28.6)  < 0.0001 34 (91.9) 9 (40.9)  < 0.0001 31 (88.6) 7 (43.8) 0.0001 34 (81.0) 2 (33.3) 0.03
 High: 4–8 6 (12.8) 10 (71.4) 3 (8.1) 13 (59.1) 4 (11.4) 9 (56.3) 8 (19.1) 4 (66.7)
 Death 7 (14.9) 1 (7.1) 0.67 7 (18.9) 1 (4.6) 0.24 7 (20.0) 1 (6.3) 0.41 7 (16.7) 0 (0.0) 0.57